Rua Life Sciences PLC (RUA) - Total Liabilities
Based on the latest financial reports, Rua Life Sciences PLC (RUA) has total liabilities worth GBX1.93 Million GBX (≈ $235.07 USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Rua Life Sciences PLC to track the company's year-over-year net asset growth rate.
Rua Life Sciences PLC - Total Liabilities Trend (1994–2025)
This chart illustrates how Rua Life Sciences PLC's total liabilities have evolved over time, based on quarterly financial data. See Rua Life Sciences PLC free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Rua Life Sciences PLC Competitors by Total Liabilities
The table below lists competitors of Rua Life Sciences PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Roquefort Investments PLC
LSE:ROQ
|
UK | GBX909.12K |
|
Ratu Prabu Energi Tbk
JK:ARTI
|
Indonesia | Rp754.04 Billion |
|
Trustco Group Holdings
JSE:TTO
|
South Africa | ZAC2.63 Billion |
|
Conygar Investment Co PLC
LSE:CIC
|
UK | GBX59.48 Million |
|
Sable Exploration and Mining Ltd
JSE:SXM
|
South Africa | ZAC6.20 Million |
|
Sprott Physical Uranium Trust
TO:U-U
|
Canada | $109.44 Million |
|
Creightons Plc
LSE:CRL
|
UK | GBX14.72 Million |
|
Shearwater Group plc
LSE:SWG
|
UK | GBX20.10 Million |
Liability Composition Analysis (1994–2025)
This chart breaks down Rua Life Sciences PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RUA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rua Life Sciences PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rua Life Sciences PLC (1994–2025)
The table below shows the annual total liabilities of Rua Life Sciences PLC from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | GBX1.89 Million ≈ $229.84 |
+1.40% |
| 2025-03-31 | GBX1.86 Million ≈ $226.67 |
+88.75% |
| 2024-03-31 | GBX987.00K ≈ $120.09 |
+0.71% |
| 2023-03-31 | GBX980.00K ≈ $119.24 |
-5.95% |
| 2022-03-31 | GBX1.04 Million ≈ $126.78 |
-36.81% |
| 2021-03-31 | GBX1.65 Million ≈ $200.64 |
+652.97% |
| 2020-03-31 | GBX219.00K ≈ $26.65 |
+121.21% |
| 2019-03-31 | GBX99.00K ≈ $12.05 |
+47.76% |
| 2018-03-31 | GBX67.00K ≈ $8.15 |
-17.70% |
| 2017-03-31 | GBX81.41K ≈ $9.90 |
-28.94% |
| 2016-03-31 | GBX114.56K ≈ $13.94 |
-30.53% |
| 2015-03-31 | GBX164.91K ≈ $20.06 |
-44.91% |
| 2014-03-31 | GBX299.38K ≈ $36.43 |
-15.77% |
| 2013-03-31 | GBX355.41K ≈ $43.24 |
-8.37% |
| 2012-03-31 | GBX387.88K ≈ $47.19 |
-41.23% |
| 2011-03-31 | GBX660.00K ≈ $80.30 |
+5.94% |
| 2010-03-31 | GBX623.00K ≈ $75.80 |
+5.41% |
| 2009-03-31 | GBX591.00K ≈ $71.91 |
-18.82% |
| 2008-03-31 | GBX728.00K ≈ $88.58 |
+1.68% |
| 2007-03-31 | GBX716.00K ≈ $87.12 |
+9.82% |
| 2006-03-31 | GBX652.00K ≈ $79.33 |
+87.36% |
| 2005-03-31 | GBX348.00K ≈ $42.34 |
-20.55% |
| 2004-03-31 | GBX438.00K ≈ $53.29 |
-81.22% |
| 2003-03-31 | GBX2.33 Million ≈ $283.74 |
-11.26% |
| 2002-03-31 | GBX2.63 Million ≈ $319.75 |
+4.37% |
| 2001-03-31 | GBX2.52 Million ≈ $306.37 |
-10.52% |
| 2000-03-31 | GBX2.81 Million ≈ $342.38 |
+113.18% |
| 1999-03-31 | GBX1.32 Million ≈ $160.61 |
-4.35% |
| 1998-03-31 | GBX1.38 Million ≈ $167.91 |
-10.62% |
| 1997-03-31 | GBX1.54 Million ≈ $187.86 |
+11.40% |
| 1996-03-31 | GBX1.39 Million ≈ $168.64 |
-27.05% |
| 1995-03-31 | GBX1.90 Million ≈ $231.18 |
+8.63% |
| 1994-03-31 | GBX1.75 Million ≈ $212.80 |
-- |
About Rua Life Sciences PLC
RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart. The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast… Read more